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ABSTRACT
Introduction: The general objective of this study
was to provide an improved software for safer
and more effective neurostimulation therapy.
Materials and Methods: Tulgar implants,
employing combined modulation of stimulation
synchronized with heart rate, breathing
frequency, and position of the patient (HBP),
were applied as vagus nerve stimulation (VNS)
for the management of refractory epilepsy in
105 patients who were followed up for 1 year.
Results: Fifty-nine out of 105 (56.19%) patients
were seizure free, 34 (32.38%) patients had
partial improvement in quality of life with a
decrease in intensity and frequency of the
seizures, and 12 (11.43%) patients did not
respond to stimulation.
Discussion: Other similar studies, undertaken
with non-Tulgar equipment, reported a 10% full
recovery, 60% partial improvement in quality of
life, and 30% zero response. Comparisons of these
results reveal an approximate fivefold increase in
seizure freedom, and threefold decrease in the
number of nonresponsive patients.
Conclusions: The findings of the present study
imply that HBP-modulated mode of stimulation
could be safer and more effective in
neurostimulation, at least in VNS.
Keywords: Epilepsy; Heart, breath and position
mode of stimulation; Neurostimulation;
Quality of life; Seizures; Tulgar implants;
Vagus nerve stimulation
INTRODUCTION
Neuroimplant is a clinical tool that stimulates the
nervous system under the skin following surgery [1].
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Neurostimulation is a process by which nerves
partially losing their function as a result of
disease or trauma are stimulated using artificial
electrical pulses for regeneration [2]. Electrical
signals used for this purpose must be consistent
with the nature of human neurophysiology [3].
Confusion resulting from chaos in electrical
parameters may lead to misuse of otherwise
clinically established neurostimulation therapy.
Earlier studies have shown that certain selected
parameters play an important role in the safety
and efficacy of the therapy for various
applications [4–15]. Whilst comprehensively
considering scientific aspects of stimulation,
the recently developed Tulgar neuroimplant
system has made possible the opportunity to
try parameters which are consistent with the
nature of the human body [16–18]. This study is
one of seven steps of a long-term research
program related to Tulgar implants: (1) the
development of a prototype model; (2) bench
testing with the prototype; (3) laboratory
tests; (4) environmental safety tests; (5)
development of clinical model that is
implantable in the living tissue; (6) animal
testing [17]; and (7) pilot implantation
in humans. The data presented in the




Since 2007, 105 patients (64 males and
41 females) suffering from refractory epilepsy
for 3–35 years participated in the study. The
patients were aged 5–69 years (mean 28.11 ±
12.90). Eighteen patients were children (14 boys
and 4 girls) aged 5–15 years (mean 10.22 ± 3.28).
MATLAB 7.5 R2007b (The MathWorks Inc., Natick,
MA, USA) was used for statistical procedure.
The subjects were experiencing two or more
tonic chronic convulsions a week, in addition to
four or more absence seizures a day despite use
of four or more anti-epileptic drugs. One patient
underwent failed resective epilepsy surgery
before this study, with only a 10% benefit in
terms of intensity and frequency. All other
patients were not indicated for resective
surgery. No patients with mental disorders
participated in the study. None of the
participants had brain tumors.
Implants
Tulgar implants were used after approval by
the Ethical Committee of the Ministry of
Health of the Republic of Turkey. Technical
specifications of the implants are explained
elsewhere [17]. The main goal of the Tulgar
neuroimplant, which is a semi-implantable
system, is that the implanted part is
completely passive, containing neither a
battery nor any active electronic components.
This allows patients to use such a breakdown-
free system for as long as they require it. There
is no risk of extra surgery for replacement of
the system that may result from electronic
failure or a limited battery life. A finger-tip
sized external compact stimulator powers and
controls the system, and is placed on the skin
overlying the implanted passive element. The
external unit is recharged by a portable charger
every 2 weeks. During recharging, patients
can use the spare external unit provided.
Programming of the external unit can easily
be achieved using a purpose-built software
located in a netbook. On the other hand,
removal of the battery and active electronic
components minimized the size of the passive
element (79% reduction in size), making it the
smallest implant available at present. The
reduction in size facilitates the surgery,
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particularly in children, and even in infants;
however, infants must be 36 months old,
following the advice of pediatric neurologists,
so that the infant brain can complete its
development [19].
Implantation
As with any vagal stimulation surgery, the left
vagus nerve was exposed by removing the
carotid sheet, and the nerve was separated
below the superior and inferior cervical
cardiac branches. A subcutaneous pocket
below the clavicle bone in the left side of the
chest was also created to house the passive
element. The passive element in the chest
pocket was secured with its silicone pad facing
the skin, and by suturing three points at the
edge of the silicone pad to the surrounding
fascia. The electrode was subcutaneously
tunneled through a guiding tube from the
pocket to the neck. Once the tip of electrode
reached the neck, the guiding tube was
removed. The electrode was attached to the
left vagus nerve by wrapping the electrode
around the vagus nerve twice. A 2–3 cm length
of electrode lead was allowed for strain relief
in both incision sides. The incisions were then
closed, with subcutaneous sutures being
permanent and the remaining sutures
cosmetic. Pre- and post-operative appropriate
antibiotics were applied. Each surgery took
approximately 1 h in addition to the
anesthetic procedure. After hospitalization
for one night, patients were sent home the
following morning.
Stimulation Parameters
One of the main features of Tulgar implants is
the application of stimulation in accordance
with the human body’s own language.
Employing Tulgar implants as vagus nerve
stimulation (VNS), the authors modulated the
stimulating signals whilst considering three
factors: (1) heart rate; (2) breathing frequency;
(3) position of the patient (HBP). Using these
factors, a HBP mode of stimulation was applied.
Physiological studies have shown that heart rate
and breathing frequency change depending on
age, sex, and position of the patient, e.g.,
standing up during daily life and lying down
during sleep [19]. Having considered these
physiological facts, the authors used eight age
groups (4–11, 12–17, 18–25, 26–35, 36–45,
46–55, 56–65, 65?) for each sex, and for both
positions. A netbook programmer operating
with purpose-built software provided 32
options to be selected after clinical
examination of each patient by the physician.
A Tulgar TI1 Model VNS Implant System
(manufactured in compliance with the
Medical Device Directive [MDD] 93/42
European Economic Community [EEC] and
Active Implantable MDD 90/385 EEC, under
patent protection, and having full quality
assurance certificates, namely CE, ISO 9001,
and ISO 13485) generated 1 min ON ? 2 min
OFF therapeutic pulses which were compatible
with cardiopulmonary activity. The other
important point related to Tulgar implants is
that a direct current-free signal is supplied.
This eliminates undesirable electrolysis
phenomena which may cause tissue necrosis
[20].
Follow-up
Each patient was followed-up for 1 year.
Stimulation started 2 weeks post-operation.
Using the graphical interface program, the
most suitable group of stimulation for each
patient was applied. Patients were invited for
control measurements in months 1, 3, 6, and 12
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following neurostimulation. During the control
measurements, the intensity and frequency of
the seizures were recorded by means of visual
analog scale (VAS) by a nurse who was blinded
for the study program. The intensity of
stimulation was increased by the programmer
when necessary.
RESULTS
By the end of the 1-year follow-up period,
59 out of 105 (56.19%) patients were seizure
free, 34 (32.38%) patients had partial
improvement in quality of life with a decrease
in frequency and intensity of the epileptic
seizures, and 12 (11.43%) patients did not
respond to stimulation. One participant, an
18-year-old girl who underwent failed resective
surgery before this study, which resulted in a
benefit of only 10% in terms of intensity and
frequency, reported a 70% improvement
(reduction in frequency and intensity of the
seizures). Among the children, 11 out of 18
(61.11%) were seizure free and five (27.78%)
had partial improvement. Only two children
(11.11%) didn’t respond to therapy. In adults,
the seizures began to stop and participants
experienced a full recovery as follows: 14 out
of 59 (23.73%) at the first control month,
17 (28.81%) at the third month, 21 (35.59%) at
the sixth month, and seven (11.86%) at the
12th month. In children, participants reported
full recovery as follows: three out of
11 (27.27%) at the first control month, four
(36.36%) at the third month, two (18.18%) at
the sixth month, and two (18.18%) at the 12th
month.
A total of 29 out of 105 (27.61%) patients
reported a reduction in the number of epileptic
seizures during the resting period of 2 weeks
following the operation and before the
stimulation began.
DISCUSSION
Having compared the results of this study with
the other similar studies undertaken with non-
Tulgar implants, there is a dramatic difference.
Similar studies have reported only a 10% full
recovery, 60% partial improvement in quality of
life, and 30% zero response [21, 22].
Comparison of these results with those of the
present study reveals an approximate fivefold
increase in seizure freedom, and a threefold
decrease in the number of nonresponsive
patients.
There are two main differences between the
Tulgar and non-Tulgar devices: (1) construction
and (2) stimulation parameters. The Tulgar
vagal stimulator is an externally powered and
controlled, semi-implantable system with
neither an implanted battery nor any active
electronic components. In contrast, non-Tulgar
devices are fully implantable systems. However,
the difference in the construction cannot be the
principle reason for the difference in results as
both devices carry out the same function:
management of refractory epilepsy. The real
difference in study results derives from the
stimulation parameters. Whilst non-Tulgar
devices supply conventional stimulation in
which pulses are repeated at a constant
frequency, the Tulgar implant system applies
completely different parameters which are
consistent with the nature of human
physiology. The authors can deduce that the
only reason for the results to be different is the
scientific algorithm of stimulation provided by
Tulgar implants.
The present study addresses the question of
whether it is really necessary to modulate the
stimulation signals and, if so, how it is
achieved? It is known that the brain
demodulates the data from the peripheral
nerve, detecting the patterns of nerve
Page 4 of 7 Neurol Ther (2012) 1:2
123
impulses, and paying particular attention to
frequency [23, 24]. Since the language that the
brain understands is frequency, it might be
worthwhile modifying the patterns of pulses
rather than keeping them constant, i.e., the
technique used in conventional mode of
stimulation. Frequency modulation of the
stimulus obviates, at least in part, this
phenomenon, and delivers essential novel
stimuli to which the nervous system responds
without adaptation [25]. Considering the earlier
scientific and clinical studies, the designing of
patterns of electrical pulses is of particular
importance. The human body is an integrated
unitary system incorporating synchronized
multifunctional sub-systems, with the nervous
system coordinating this system. The language
of the nervous system should be consistent with
the other ongoing activities, such as
cardiopulmonary activity. Furthermore, the
body’s own language also has to be considered
when modulating the frequency, as modulation
must be combined with other factors, such as
heart rate and breathing frequency depending
on age and sex, as well as the position of patient
(standing up or lying down).
With regards to secondary outcomes, the
reduction in epileptic seizures during post-
operative resting time experienced by some
participants might be explained by a
mechanical stimulation effect resulting from
the manipulation of the vagus nerve during
surgery, and touching of the electrode to the
neighboring tissue following surgery.
Furthermore, another outcome of the present
study is that, with these dramatic positive
changes in the results in mind, improved VNS
seems to be more cost-effective versus drug
therapy for the management of refractory
epilepsy [26].
The authors are, of course, aware that the
alternative vagal stimulators have been
studied in larger numbers of patients since
1997; however, the 105 patients included in
the present study is not a neglectable
population.
CONCLUSION
The findings of the present study imply that
HBP-modulated mode of stimulation could be
safer and more effective in neurostimulation, at
least in VNS, and worth applying in extensive
studies which include a larger number of
patients.
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